---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-151393"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-06-27T23:59:59+00:00"
generated_at: "2026-05-18T16:23:41.849981+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera prices $250.8M public offering of common stock and pre-funded warrants

## Summary
- Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.
- Net proceeds estimated at $237.3M (or $272.7M if underwriters option for 855K shares exercised).
- Proceeds to advance preclinical/clinical degrader programs and for working capital.
- Existing cash plus offering proceeds expected to fund operations into mid 2028.
- Company also entered registration rights agreement with Baker, Atlas, and BVF affiliates for up to 27.96M resale shares.

## SEC filing metadata
- accession: 0001193125-25-151393
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/0001193125-25-151393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/d85382d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-151393
- JSON: https://secwatch.observer/filing/0001193125-25-151393.json
- Plain text: https://secwatch.observer/filing/0001193125-25-151393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.